ArticleBlood2017
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Guideline
- Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.Blood advances · 2021Trial
- Trial
- DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.Blood advances · 2026Article
- Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.Blood advances · 2026Review
- RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.Cancer cell · 2026Article
- Efficacy of Combined Dabrafenib and Trametinib Therapy in BRAFV600E Mutant Intrahepatic Cholangiocarcinoma with a Neurofibromatosis Type 2 Mutation.Internal medicine (Tokyo, Japan) · 2025Article
- Article
- Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFBMC chemistry · 2025Article
- CD103-Negative Hairy Cell Leukemia: A Case Report From University Teaching Hospital, Zambia.Case reports in medicine · 2025Article
- Immune activation and microenvironmental crosstalk in hairy cell leukemia.Frontiers in immunology · 2025Review
- B Cell Differentiation and the Origin and Pathogenesis of Human B Cell Lymphomas.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations.Annals of hematology · 2024Article
- Genetic alterations in mature B- and T-cell lymphomas - a practical guide to WHO-HAEM5.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2024Article
- Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment.Journal of cellular and molecular medicine · 2024Review
- U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review).Oncology reports · 2024Review
- Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia.Nature cancer · 2023Article
- The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2023Review
- BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes.Molecular cancer · 2023Article
- Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.Blood advances · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 3 countries.
Benjamin H DurhamDepartment of Pathology and.
Bartlomiej GettaLeukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
Sascha DietrichDepartment of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Justin TaylorHuman Oncology and Pathogenesis Program and.
Helen WonHuman Oncology and Pathogenesis Program and.
James M BogenbergerDivision of Hematology and Medical Oncology, Mayo Clinic/Mayo Clinic Cancer Center, Scottsdale, AZ.
Sasinya ScottHuman Oncology and Pathogenesis Program and.
Eunhee KimSchool of Life Sciences, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea.
Young Rock ChungHuman Oncology and Pathogenesis Program and.
Stephen S ChungHuman Oncology and Pathogenesis Program and.
Jennifer HülleinDepartment of Molecular Therapy in Hematology and Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
Tatjana WaltherDepartment of Molecular Therapy in Hematology and Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
Lu WangDepartment of Pathology and.
Sydney X LuHuman Oncology and Pathogenesis Program and.
Christopher C OakesDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Raoul TibesDivision of Hematology and Medical Oncology, Mayo Clinic/Mayo Clinic Cancer Center, Scottsdale, AZ.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany; and.
Barry S TaylorHuman Oncology and Pathogenesis Program and.
Martin S TallmanLeukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
Michael F BergerHuman Oncology and Pathogenesis Program and.
Jae H ParkLeukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
Thorsten ZenzDepartment of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Omar Abdel-WahabLeukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0002-3907-6171
Memorial Sloan Kettering Cancer Center · USGerman Cancer Research Center · DEMayo Clinic in Arizona · USMunich Leukemia Laboratory (Germany) · DEThe Ohio State University · USUlsan National Institute of Science and Technology · KR
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MGenetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0MOrigins of BRAF-mutant hematologic malignancies and their therapeutic resistanceR01CA201247 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, PARK, CHRISTOPHER Y · 2016 to 2020
$2.7MRole of ASXL1 mutations in myeloid malignanciesK08CA160647 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR · 2011 to 2015
$849kNCI NIH HHS K08 CA160647NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA201247NHLBI NIH HHS R01 HL128239
Abstract
Classical hairy cell leukemia (cHCL) is characterized by a near 100% frequency of the
Indexed as
MutationAntineoplastic AgentsCyclin D3Cyclin-Dependent Kinase Inhibitor p27DNA-Binding ProteinsDrug Resistance, NeoplasmGenomicsHumansIndolesLeukemia, Hairy CellMAP Kinase Kinase 1Proto-Oncogene Proteins B-rafSplicing Factor U2AFSulfonamidesVemurafenibAntineoplastic AgentsCCND3 protein, humanCDKN1B protein, humanCyclin D3Cyclin-Dependent Kinase Inhibitor p27DNA-Binding ProteinsIndolesKMT2C protein, humanMAP2K1 protein, humanMAP Kinase Kinase 1Proto-Oncogene Proteins B-rafSplicing Factor U2AFSulfonamidesU2AF1 protein, humanVemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.